CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is 68.9%, higher than 95% of its Biotechnology peers (median -24.5%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.65BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
194.89%vs all stocks
Market Capitalization
4.65BUSDvs all stocks (USD)
Enterprise Value
4.30BUSDvs all stocks (USD)
Forward P/E
-34.72xvs Biotechnology peers
Price to Book (MRQ)
10.12xvs Biotechnology peers
Enterprise to EBITDA
-61.39xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-54.63%vs Biotechnology peers
Return on Equity (TTM)
68.90%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-98.80MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-79.45MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-71.56MUSDvs all stocks (USD)
Pre-tax Income
-70.00MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-70.00MUSDFY2025 · Dec 31, 2025EBIT
-70.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-70.00MUSDFY2025 · Dec 31, 2025Research & Development
62.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
10.28MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-790.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.56MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025EPS (Basic)
-2.38USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.38USDFY2025 · Dec 31, 2025Basic Shares Outstanding
35.08MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
35.08MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-70.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-67.88MUSDFY2025 · Dec 31, 2025Free Cash Flow
-67.90MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
21.77MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-70.00MUSDFY2025 · Dec 31, 2025Stock-based Compensation
1.44MUSDFY2025 · Dec 31, 2025Other Non-cash Items
839.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-122.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-39.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-24.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-143.85MUSDFY2025 · Dec 31, 2025Sale of Investments
25.02MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-118.86MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-447.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
158.99MUSDFY2025 · Dec 31, 2025Shares Outstanding
37.34MSharesUpdated Jul 19, 2026Float Shares
27.21MSharesUpdated Jul 19, 2026Shares Short
3.81MSharesUpdated Jul 19, 2026Short Ratio
5.22daysvs all stocks
Short % of Shares Outstanding
14.00%vs all stocks
% Held by Insiders
2.74%vs all stocks
% Held by Institutions
80.00%vs all stocks
Total Cash (MRQ)
390.80MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.35USDUpdated Jul 19, 2026Total Debt (MRQ)
0.00USDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0000xvs Biotechnology peers
Current Ratio (MRQ)
59.12xvs Biotechnology peers
Book Value per Share (MRQ)
10.46USDUpdated Jul 19, 2026Total Assets
152.62MUSDvs all stocks (USD)
Total Current Assets
152.49MUSDFY2025 · Dec 31, 2025Total Liabilities
273.63MUSDFY2025 · Dec 31, 2025Total Non-current Assets
125.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
264.48MUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.15MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
21.77MUSDFY2025 · Dec 31, 2025Other Short-term Investments
120.10MUSDFY2025 · Dec 31, 2025Accounts Payable
2.13MUSDFY2025 · Dec 31, 2025Other Current Liabilities
47.00KUSDFY2025 · Dec 31, 2025Long-term Debt
4.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-123.42MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-121.01MUSDvs all stocks (USD)
52-Week Low
32.00USDUpdated Jul 19, 202652-Week High
131.24USDUpdated Jul 19, 202652-Week Change
194.89%vs all stocks
50-Day MA
106.80USDUpdated Jul 19, 2026200-Day MA
81.11USDUpdated Jul 19, 2026Avg 10-Day Volume
617.72KSharesUpdated Jul 19, 2026Avg 30-Day Volume
709.87KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.26USDUpdated Jul 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 68.9%, higher than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: 0.69Industry median: -0.25Industry P95: 0.23Peers compared: 197
Current ratio is 59.12×, higher than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 59.12Industry median: 5.50Industry P95: 22.03Peers compared: 197
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.1×)Notable
Debt-to-equity: 0.00Industry median: 0.10Industry P5: 0.00Peers compared: 197
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.59
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $4.65B, above the global median of $1.15BNotable
Market cap (USD): 4,650,803,436Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Tango Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Mgi Tech Co Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Crispr Therapeutics AG
Tier 1ProductionApproval-Gated PipelineRule
Ajanta Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Simcere Pharmaceutical Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Indivior Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
LivaNova PLC
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sk Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule